Tharimmune (THAR) Competitors $3.60 +0.94 (+35.34%) Closing price 04:00 PM EasternExtended Trading$2.98 -0.62 (-17.19%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. INKT, MGX, PRLD, PMVP, SLGL, VNRX, CVM, ARTV, ALGS, and ANLShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include MiNK Therapeutics (INKT), Metagenomi (MGX), Prelude Therapeutics (PRLD), PMV Pharmaceuticals (PMVP), Sol-Gel Technologies (SLGL), VolitionRx (VNRX), CEL-SCI (CVM), Artiva Biotherapeutics (ARTV), Aligos Therapeutics (ALGS), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors MiNK Therapeutics Metagenomi Prelude Therapeutics PMV Pharmaceuticals Sol-Gel Technologies VolitionRx CEL-SCI Artiva Biotherapeutics Aligos Therapeutics Adlai Nortye MiNK Therapeutics (NASDAQ:INKT) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations. Is INKT or THAR more profitable? MiNK Therapeutics' return on equity of 0.00% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -227.24% Tharimmune N/A -1,239.20%-365.06% Do institutionals and insiders hold more shares of INKT or THAR? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, INKT or THAR? MiNK Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Does the media refer more to INKT or THAR? In the previous week, MiNK Therapeutics had 6 more articles in the media than Tharimmune. MarketBeat recorded 6 mentions for MiNK Therapeutics and 0 mentions for Tharimmune. MiNK Therapeutics' average media sentiment score of 1.02 beat Tharimmune's score of 0.98 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Overall Sentiment MiNK Therapeutics Positive Tharimmune Positive Do analysts prefer INKT or THAR? MiNK Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 148.51%. Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 372.22%. Given Tharimmune's stronger consensus rating and higher probable upside, analysts clearly believe Tharimmune is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has higher valuation and earnings, INKT or THAR? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.24TharimmuneN/AN/A-$12.20M-$6.10-0.59 SummaryMiNK Therapeutics beats Tharimmune on 9 of the 13 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.14M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-0.5920.5276.4826.75Price / SalesN/A446.54531.95124.23Price / CashN/A46.0037.9261.55Price / Book5.299.6613.726.40Net Income-$12.20M-$53.02M$3.29B$271.62M7 Day Performance14.65%1.09%1.03%2.85%1 Month Performance207.69%7.93%6.32%9.64%1 Year Performance20.40%10.48%81.16%31.62% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.5798 of 5 stars$3.60+35.3%$17.00+372.2%-9.5%$15.14MN/A-0.592Gap DownINKTMiNK Therapeutics3.6753 of 5 stars$15.29-0.5%$37.50+145.3%+107.4%$69.11MN/A-5.3130News CoveragePositive NewsShort Interest ↓Gap UpMGXMetagenomi2.3503 of 5 stars$1.84-1.1%$10.00+443.5%-19.5%$69.06M$33.77M-0.78236Positive NewsPRLDPrelude Therapeutics3.037 of 5 stars$1.19flat$4.00+236.1%-58.6%$67.35M$7M-0.73120PMVPPMV Pharmaceuticals2.937 of 5 stars$1.27-20.6%$5.50+333.1%-18.5%$67.30MN/A-0.8150Gap UpHigh Trading VolumeSLGLSol-Gel Technologies0.6667 of 5 stars$23.95-7.6%N/A+304.4%$66.82M$11.54M-19.4750Gap UpVNRXVolitionRx1.9288 of 5 stars$0.62-2.5%$3.50+463.7%+1.6%$66.81M$1.32M-1.7280CVMCEL-SCI1.1945 of 5 stars$9.68-9.4%N/A-73.9%$66.62MN/A-20.1743Positive NewsShort Interest ↓ARTVArtiva Biotherapeutics2.5637 of 5 stars$2.70-2.9%$17.00+529.6%-80.0%$65.95MN/A0.0081ALGSAligos Therapeutics3.7726 of 5 stars$10.71-4.5%$50.00+366.9%-29.4%$65.88M$3.17M-0.5490Positive NewsANLAdlai Nortye1.9781 of 5 stars$1.77+2.9%$9.00+408.5%-21.4%$65.31MN/A0.00127Positive NewsGap Up Related Companies and Tools Related Companies MiNK Therapeutics Competitors Metagenomi Competitors Prelude Therapeutics Competitors PMV Pharmaceuticals Competitors Sol-Gel Technologies Competitors VolitionRx Competitors CEL-SCI Competitors Artiva Biotherapeutics Competitors Aligos Therapeutics Competitors Adlai Nortye Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
